|Dr. James P. Gilligan MSIB, Ph.D.||Interim CEO, Pres & Chief Scientific Officer||137.49k||N/A||1952|
|Dr. James S. Kuo M.B.A., M.D.||Co-Founder & Director||69.44k||N/A||1965|
|Mr. Jim O'Neill||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Thomas D'Orazio B.Sc., M.B.A.||Chief Operating Officer||N/A||N/A||N/A|
|Mr. Sidney Taubenfeld R.Ph||Chief Operating Officer||N/A||N/A||N/A|
|Ms. Joy Willis||Director of Investor Relations||N/A||N/A||N/A|
Tryp Therapeutics Inc., a pharmaceutical company, focuses on identifying and developing compounds for diseases with high unmet medical needs. The company's lead development program is (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 and TRP-8803 for fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. The company has an agreement with the Calvert Labs to design and execute exploratory studies related to psilocybin-for-neuropsychiatric disorders program; and a service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was incorporated in 2019 and is based in Kelowna, Canada.
Tryp Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.